This study aimed to report the affinity, competitive blocking capability, T cell activation effect, Fc-mediated effector functions, preliminary anti-tumor activity, RO, and PK of GLS-010, a novel fully human anti-PD-1 monoclonal IgG4 (26, 27). This evidence concerns the gene PDCD1 and neoplasm.